Cidara Therapeutics, Inc.
CDTX
Classement en actions
#3183
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Prix de l'action
$221.38
Dernière synchronisation: 2026-01-08
Capitalisation boursière
$5.61B
Changement (1 jour)
0.00%
Changement (1 an)
118.07%
Pays
US
Échange Cidara Therapeutics, Inc. (CDTX)
Catégorie
Healthcare
EPS pour Cidara Therapeutics, Inc. (CDTX)
EPS au September 2025 TTM : $-11.78
Selon les derniers rapports financiers et le cours de l'action de Cidara Therapeutics, Inc., l’EPS actuel de la société (TTM) est de $-11.78. À la fin de 2023, la société avait un EPS de $-5.25 une diminution par rapport à celui de 2022, qui était de $-9.61.
Historique de l'EPS de Cidara Therapeutics, Inc. de 2012 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-11.78 | -55.96% |
| 2024 | $-26.75 | 409.52% |
| 2023 | $-5.25 | -45.37% |
| 2022 | $-9.61 | -40.68% |
| 2021 | $-16.20 | -55.04% |
| 2020 | $-36.03 | 34.54% |
| 2019 | $-26.78 | -41.30% |
| 2018 | $-45.62 | -28.37% |
| 2017 | $-63.69 | -4.21% |
| 2016 | $-66.49 | 42.19% |
| 2015 | $-46.76 | -83.88% |
| 2014 | $-290.15 | 249.41% |
| 2013 | $-83.04 | 85.77% |
| 2012 | $-44.70 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -247.03% |
US
|
|
| $-7.98 | -32.26% |
US
|
|
| $-5.29 | -55.09% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -335.48% |
NL
|
